Conduit Pharmaceuticals Inc. has been the subject of an amended Schedule 13G filing with the United States Securities and Exchange Commission (SEC), dated August 13, 2024. The amendment, which supplements the original filing from October 2, 2023, discloses that Nirland Limited, along with related entities Stockton Limited, The Rowland Master Trust, and Dovet Limited, collectively hold a 14.8% ownership stake in Conduit Pharmaceuticals. This stake amounts to 14,500,000 shares of common stock. The shares include 12,500,000 directly issued to Nirland Limited and an additional 2,000,000 shares potentially issuable upon the exercise of a common stock warrant. The entities are all registered in Guernsey and are interconnected through ownership and trust relationships, with Dovet Limited acting as the sole trustee of The Rowland Master Trust, which wholly owns Stockton Limited, which in turn owns Nirland Limited. The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of Conduit Pharmaceuticals.

Conduit Pharmaceuticals Inc. has been the subject of an amended Schedule 13G filing with the United States Securities and Exchange Commission (SEC), dated August 13, 2024. The amendment, which supplements the original filing from October 2, 2023, discloses that Nirland Limited, along with related entities Stockton Limited, The Rowland Master Trust, and Dovet Limited, collectively hold a 14.8% ownership stake in Conduit Pharmaceuticals. This stake amounts to 14,500,000 shares of common stock. The shares include 12,500,000 directly issued to Nirland Limited and an additional 2,000,000 shares potentially issuable upon the exercise of a common stock warrant. The entities are all registered in Guernsey and are interconnected through ownership and trust relationships, with Dovet Limited acting as the sole trustee of The Rowland Master Trust, which wholly owns Stockton Limited, which in turn owns Nirland Limited. The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of Conduit Pharmaceuticals.